[Measurement of outpatient treatment costs of chronic inflammatory bowel diseases at a German university hospital].
OBJECTIVE
To create a concept for measuring and valuating resource utilization of outpatient treatment of patients with inflammatory bowel disease in a German university hospital.


METHODS
The measurement of health services was achieved using a computer-based routinely administered data base of the Medical Department. Measuring costs was performed in three steps: 1. identification of the categories of resource utilization, 2. quantitative measurement of resource use, 3. monetary valuation of the utilization of resources using German fee schedules and prices for drugs.


RESULTS
The resource utilization of 272 patients with a treatment period of more than 1 year could be identified in a structured form. Categories of resource use could be identified and quantitatively measured as follows: anamnesis and physical examination by a physician in 100% of the visits, laboratory tests in 87.1%, endoscopic or sonographic services in 36.9%, and radiologic procedures in 14.1%. In 93.6% of the visits a medication was prescribed. Annual costs of outpatient care provided by the hospital were 3,171 [symbol: see text] per patient. Medication accounted for 85% of total costs. Analyzing the costs of medical treatment, mesalazine was the major cost component (48%), followed by budesonide (15%).


CONCLUSIONS
The presented concept offers a good access to measure costs of outpatient treatment of patients with inflammatory bowel disease. It is suitable for measuring costs in the economic evaluation of alternative treatments or diagnostic strategies in an outpatient setting. It furthermore may be used as a component in cost-of-illness studies. For transferring the concept to other hospitals, the availability of a routine documentation of services should be checked. For economic analysis, a further data management is required.
Rösch
Margrit
M
Abteilung Gesundheitsökonomie, Medizinische Universitäts- und Poliklinik, Universität Ulm. margrit.roesch@mathematik.uni-ulm.de
Leidl
Reiner
R
Thomas
Stefanie
S
von Tirpitz
Christian
C
Reinshagen
Max
M
Adler
Guido
G
König
Hans-Helmut
HH
D000328:Adult; D000553:Ambulatory Care / Q000191:economics*; D000893:Anti-Inflammatory Agents / Q000191:economics / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics / Q000627:therapeutic use; D019819:Budesonide / Q000191:economics / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000191:economics*; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D003424:Crohn Disease / Q000188:drug therapy / Q000191:economics*; D016527:Drug Costs; D005858:Germany; D017048:Health Care Costs; D006295:Health Resources / Q000191:economics / Q000706:statistics & numerical data; D006785:Hospitals, University / Q000191:economics*; D006801:Humans; D019804:Mesalamine / Q000191:economics / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine; D019819:Budesonide